Document is current
Any future updates will be listed below
-
Authors
Di Nicolantonio, Federica https://orcid.org/0000-0001-9618-2010
Bardelli, Alberto https://orcid.org/0000-0003-1647-5070
- License Information
-
More Information
Article History
First Online: 13 March 2023
Competing interests
: F.D.N. has received speaker’s fees from Pierre Fabre for participating in an advisory board meeting relating to encorafenib. A.B. reports receiving commercial research grants from AstraZeneca, Boehringer Ingelheim and Neophore; is an advisory board member/unpaid consultant for Inivata and Neophore; has ownership interest in Neophore; and is an advisory board member/consultant for Guardant Health, Illumina, Inivata and Roche/Genentech.
